Drugs / DAVALINTIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00785408 | Dec 2008 → Sep 2009 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAVALINTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105635 ↗ |
| Known as | AC2307 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00785408 ↗ |
| Known as | Davalintida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105635 ↗ |
| Known as | DAVALINTIDE ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105635 ↗ |
| Action | Activate | “Calcitonin gene-related peptide type 1 receptor agonist” CHEMBL2105635 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2105635 ↗ |
| Route | Subcutaneous | “subcutaneous, twice daily, low dose” NCT00785408 ↗ |
| Target | CALCRL | “Calcitonin gene-related peptide type 1 receptor agonist” CHEMBL2105635 ↗ |